Fractyl Health, Inc. (GUTS)
| Market Cap | 12.19M -91.8% |
| Revenue (ttm) | n/a |
| Net Income | -105.65M |
| EPS | -9.71 |
| Shares Out | 13.26M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,891 |
| Open | 0.8825 |
| Previous Close | 0.8958 |
| Day's Range | 0.8825 - 0.9484 |
| 52-Week Range | 0.8207 - 29.3400 |
| Beta | 2.89 |
| Analysts | Strong Buy |
| Price Target | 23.60 (+2,468.01%) |
| Earnings Date | Nov 12, 2026 |
About GUTS
Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably alteri... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for GUTS stock is "Strong Buy." The 12-month stock price target is $23.6, which is an increase of 2,468.01% from the latest price.
News
Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026
BURLINGTON, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approache...
Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization
BURLINGTON, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approache...
Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance
Company estimates approximately one million U.S. patients each month discontinue GLP-1 medications and face the risk of weight regain One-third of surveyed GLP-1 users expressed a preference for an en...
Fractyl Health cuts about 45% of workforce to focus on Revita
Fractyl Health (GUTS) announced that it is sharpening its focus and concentrating its financial and operational resources on advancing Revita, its lead product candidate, toward potential FDA marketin...
Fractyl Health ends Rejuva development, sees cash runway into Q2 2027
Fractyl Health (GUTS) announced it will discontinue internal development of its Rejuva gene therapy program and is seeking strategic alternatives to maximize the value of the program. There can be…
Fractyl Health co-founder Jay Caplan to retire, continue as advisor
Fractyl Health (GUTS) announced that Jay Caplan, co-founder, president and chief product officer, will retire from his executive roles effective October 30. Caplan is expected to continue as a senior…
Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance
Following positive topline six-month REMAIN-1 pivotal results, Revita advancing toward planned FDA De Novo submission in late Q4 2026 and anticipated 12-month pivotal data readout in Q1 2027 Workforce...
Fractyl Health price target lowered to $39 from $96 at Canaccord
Canaccord analyst Whitney Ijem lowered the firm’s price target on Fractyl Health (GUTS) to $39 from $96 and keeps a Buy rating on the shares. The firm updated its model…
Fractyl Health price target lowered to $5 from $48 at Craig-Hallum
Craig-Hallum lowered the firm’s price target on Fractyl Health (GUTS) to $5 from $48 and keeps a Buy rating on the shares. The firm notes Fractyl announced statistically significant top-line…
Fractyl Health Stock (GUTS) Sinks Over 58% on Trial Results and a Lawsuit
Fractyl Health stock fell after the company posted results from a clinical trial and was named in a lawsuit.
Fractyl Health Transcript: Study update
Revita met its six-month REMAIN-1 co-primary comparison, retaining 80% of GLP-1-induced weight loss versus 67% with sham (P=0.0023). Twelve-month results are expected in Q1 2027, with De Novo preparation and access planning underway.
Fractyl Health Slides: Study update
Fractyl Health has posted slides in relation to its latest quarterly earnings report, which was published on October 16, 2026.
Fractyl Health Press release: Study update
Fractyl Health issued a press release on October 16, 2026, disclosing material business information to investors.
Fractyl Health announces REMAIN-1 study meets six-month co-primary endpoint
Fractyl Health (GUTS) announced topline six-month results from the Pivotal Cohort of its ongoing REMAIN-1 study, a 308-participant, multicenter, randomized, double-blind, sham-controlled study of the ...
Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
REMAIN-1 met its six-month co-primary endpoint with high statistical significance (p=0.0023; mITT population); demonstrated 80% retention of GLP-1 induced weight loss vs 67% for sham
Fractyl Health Inc trading halted, news pending
19:50 EDT Fractyl Health (GUTS) Inc trading halted, news pending
Shareholders Sue Fractyl (GUTS) Over Weight Loss Drug Claims
A class action lawsuit was filed against Fractyl Health ($GUTS) on August 21, 2026. Plaintiffs in the federal securities lawsuit allege that they acquired Fractyl stock at artificially inflated prices...
Robbins LLP is Investigating Allegations that Fractyl Health, Inc. Misled Investors Regarding the Viability and Efficacy of its Revita DMR System
San Diego, California--(Newsfile Corp. - September 29, 2026) - Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchas...
Fractyl Health Transcript: EGM 2026
Stockholders approved a proposal granting the board authority to enact a reverse stock split at a ratio between 1-for-5 and 1-for-15. Quorum was achieved, and no questions were submitted. Final voting results will be published in a Form 8-K.
GUTS Stockholders Have Rights – If you Lost Money Investing in Fractyl Health, Inc. Contact Robbins LLP for Information About Recovering Your Losses
SAN DIEGO--(BUSINESS WIRE)---- $GUTS #Fractyl--Shareholder rights law firm Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities who purchased or otherwise ...
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of October 20, 2026 in Fractyl Health, Inc. Lawsuit - GUTS
Two named officers of Fractyl Health, Inc. — Co-Founder and CEO Harith Rajagopalan and former CFO Lisa A. Davidson — face Section 20(a) control person claims over allegedly overstated Revita DMR effic...
Fractyl Health Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
Revita is positioned as a durable, outpatient solution for post-GLP-1 weight maintenance, with pivotal data and a regulatory filing expected soon. The commercial strategy targets top bariatric centers, leveraging existing infrastructure and a favorable safety profile. CMS policy and early coverage for Breakthrough Devices could be major growth drivers.
Fractyl Health Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Durable weight maintenance after GLP-1 discontinuation is a critical unmet need, addressed by Revita's device-based approach, which has shown strong efficacy and safety in clinical studies. Regulatory and commercial strategies are aligned for a potential U.S. launch in 2027, with pivotal data expected in early Q4 2026.
Fractyl Health to Participate in Upcoming September Investor Conferences
BURLINGTON, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a clinical stage metabolic therapeutics company focused on pioneering novel approach...
Fractyl Health Transcript: Status update
Post-GLP-1 weight regain is a major unmet need, with millions of patients lacking durable maintenance options. Revita, a one-time endoscopic procedure, shows strong efficacy and safety, with a large addressable market and a focused commercialization plan targeting high-volume centers. Break-even is projected within 5-8 quarters post-launch, leveraging favorable reimbursement dynamics.